Latest news with #GILD
Yahoo
09-07-2025
- Business
- Yahoo
Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update
Gilead Sciences, Inc. (NASDAQ:) is one of the . Bridgewater Associates holds over $56 million worth of shares of GILD, which represents 0.26% of its portfolio. A closeup shot of a laboratory technician handling a medical device used for fertility treatments. On June 26, 2025, Gilead Sciences, Inc. (NASDAQ:GILD) announced the development of its ongoing Phase 2/3 clinical trial that is expected to treat HIV in pediatric patients. The study began in January 2014. It is focused on evaluating the safety, dosage, and effectiveness of cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted Darunavir (DRV/co), and Emtricitabine/Tenofovir Alafenamide (F/TAF) in participants with virologically suppressed HIV-1. This development highlights the company's continued commitment to advancing antiretroviral therapies for all age groups. Given the limited number of competitors in the pediatric HIV market, this progress is expected to strengthen Gilead Sciences, Inc.'s (NASDAQ:GILD) market position and boost investors' confidence. Gilead Sciences, Inc. (NASDAQ:GILD), a U.S.-based biopharmaceutical company, researches and develops antiviral drugs for patients with HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. GILD is among the list of cheap stocks to buy. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and 10 Best Marketing Stocks to Buy Right Now. Disclosure: None.
Yahoo
08-07-2025
- Business
- Yahoo
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Gilead Sciences (GILD) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Gilead Sciences is a member of the Medical sector. This group includes 987 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Gilead Sciences is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for GILD's full-year earnings has moved 0.7% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger. Based on the latest available data, GILD has gained about 21% so far this year. In comparison, Medical companies have returned an average of -4.7%. This means that Gilead Sciences is outperforming the sector as a whole this year. Alignment Healthcare (ALHC) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 16.8%. In Alignment Healthcare's case, the consensus EPS estimate for the current year increased 16.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy). To break things down more, Gilead Sciences belongs to the Medical - Biomedical and Genetics industry, a group that includes 495 individual companies and currently sits at #77 in the Zacks Industry Rank. This group has lost an average of 2.9% so far this year, so GILD is performing better in this area. On the other hand, Alignment Healthcare belongs to the Medical Services industry. This 58-stock industry is currently ranked #56. The industry has moved -2.8% year to date. Going forward, investors interested in Medical stocks should continue to pay close attention to Gilead Sciences and Alignment Healthcare as they could maintain their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Alignment Healthcare, Inc. (ALHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-06-2025
- Business
- Yahoo
Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a significant setback after the US Food and Drug Administration put on hold studies of several of its HIV drugs on June 11. kurhan / The FDA placed a hold on the HIV treatment trial of GS-1720 and GS-4182 on the identification of the safety signal of a decrease in CD4+ T-cells in trials. Gilead insists it is collaborating with authorities and working to resolve underlying issues. However, the FDA hold did not in any way affect multiple other HIV treatment combinations that the company is working on. The combination is one of the several drugs that Gilead is working on to replace any revenue it could lose in case its bestselling HIV drug, Biktarvy, loses patent protection. Gilead Sciences Inc. (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. Each discovery and investigational drug candidate seeks to improve the care of patients living with life-threatening diseases worldwide. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-06-2025
- Business
- Yahoo
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Gilead Sciences (GILD). Gilead currently has an average brokerage recommendation (ABR) of 1.72, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 29 brokerage firms. An ABR of 1.72 approximates between Strong Buy and Buy. Of the 29 recommendations that derive the current ABR, 18 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 62.1% and 3.5% of all recommendations. Check price target & stock forecast for Gilead here>>> While the ABR calls for buying Gilead, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential. Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation. In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. Although both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether. Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide. On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks. There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices. In terms of earnings estimate revisions for Gilead, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $7.91. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Gilead. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Gilead. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
11-06-2025
- Business
- Yahoo
FDA placed clinical hold on Gilead HIV treatment trials of GS-1720
The Food and Drug Administration has placed a clinical hold on Gilead's (GILD) HIV treatment trials of GS-1720 and/or GS-4182, the company said in a statement. The clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182, the company explained. It added, 'Clinical trial investigators involved in the trials have been informed of these actions. GS-1720 and GS-1482 are investigational agents and have not been approved anywhere globally. We intend to investigate and pursue the potential of both agents and are committed to working with regulatory authorities to resolve the issues underlying the clinical hold. Gilead has multiple other long-acting oral and injectable investigational HIV treatment combinations under evaluation in clinical and preclinical studies, including combinations with weekly, monthly, quarterly, and twice-yearly dosing. This hold does not impact these combinations or their respective clinical or pre-clinical development programs.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on GILD: Disclaimer & DisclosureReport an Issue Gilead Sciences: Strong Market Position and Growth Potential Drive Buy Rating Gilead Sciences' Oncology Advancements: Trodelvy's Potential to Boost Stock Value Gilead Sciences: Promising Pipeline and Strategic Advancements Justify Buy Rating Gilead Sciences: Buy Rating Driven by Promising HIV Treatment Pipeline and Strategic Growth Prospects Gilead Sciences: Buy Rating Affirmed on Promising Oncology Pipeline and Trodelvy's Potential as New Standard of Care
